本文選題：前列地爾脂微球注射劑 + 平均日劑量　； 參考：《中國藥房》2017年14期

【摘要】：目的:為前列地爾脂微球注射劑(Lipo-PGE1)的合理應用和監(jiān)管提供依據(jù)。方法:以來源于全國159家醫(yī)院醫(yī)院信息系統(tǒng)中使用Lipo-PGE1的成年住院患者為研究對象,基于頻數(shù)統(tǒng)計法對Lipo-PGE1的臨床使用人群、臨床診斷和平均日劑量進行研究。結果:共71 687例成年住院患者納入統(tǒng)計,使用Lipo-PGE1的男性住院患者明顯多于女性,年齡61~75歲的患者最多。患者住院天數(shù)主要分布在8~14 d(45.01%),治療結果以好轉為主(68.20%)。Lipo-PGE1臨床使用廣泛,共涉及871種臨床主要診斷,列前3位的是腦梗死(9.06%)、非胰島素依賴型糖尿病(8.65%)和慢性缺血性心臟病(8.08%)。不同疾病和不同醫(yī)院Lipo-PGE1的平均日劑量差異較大,且以≤12.5μg居多。結論:Lipo-PGE1作為輔助用藥,需要醫(yī)療機構及相關監(jiān)管部門制訂合理的監(jiān)管指標并加強用藥指導及用藥點評。
[Abstract]:Objective: to provide evidence for rational application and supervision of Lipo-PGE1. Methods: adult inpatients who used Lipo-PGE1 in the hospital information system of 159 hospitals all over the country were studied on the basis of frequency statistics to study the clinical use, clinical diagnosis and average daily dose of Lipo-PGE1. Results: a total of 71,687 adult inpatients were included in the study. Male patients with Lipo-PGE1 were significantly more than women, and the majority of patients were aged 61to 75 years. The days of hospitalization were mainly distributed in 814 days and 45.01%. The treatment results were mainly improved by 68.20% and 68.20%. Lipo-PGE1 was widely used in clinic, involving 871 main clinical diagnoses. The top three were cerebral infarction (9.06), non-insulin dependent diabetes (8.65) and chronic ischemic heart disease (8.08). The average daily dose of Lipo-PGE1 was significantly different among different diseases and hospitals, and was mainly 鈮，

本文編號：1778100